Spleen tyrosine kinase: An Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases

References

• Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem. 2001; 130:177–186.
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Kobayashi T, Kondo J, Takahashi K, Nakamura H, Suzuki J, Nagai K, Yamada T, Nakamura S, Yamamura H. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem. 1991; 266:15790–15796.
   PubMed Web of Science ®Google Scholar
• Sakai K, Tanaka Y, Asahi M, Shimomura R, Taniguchi T, Hashimoto E, Yamamura H. Identification of the phosphorylation sites of H2B histone by a catalytic fragment of p72syk from porcine spleen. FEBS Lett. 1991; 294:104–108.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Kung HJ. Signaling network of the Btk family kinases. Oncogene. 2000; 19:5651–5661.
   PubMed Web of Science ®Google Scholar
• Muljo SA, Schlissel MS. Pre-B and pre-T-cell receptors: Conservation of strategies in regulating early lymphocyte development. Immunol Rev. 2000; 175:80–93.
   PubMed Web of Science ®Google Scholar
• Futterer K, Wong J, Grucza RA, Chan AC, Waksman G. Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol. 1998; 281:523–537.
   PubMed Web of Science ®Google Scholar
• Hatada MH, Lu X, Laird ER, Green J, Morgenstern JP, Lou M, Marr CS, Phillips TB, Ram MK, Theriault K, Zoller MJ, Karas JL. Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor. Nature. 1995; 377:32–38.
   PubMed Web of Science ®Google Scholar
• Au-Yeung BB, Deindl S, Hsu LY, Palacios EH, Levin SE, Kuriyan J, Weiss A. The structure, regulation, and function of ZAP-70. Immunol Rev. 2009; 228:41–57.
   PubMed Web of Science ®Google Scholar
• Kurosaki T. Functional dissection of BCR signaling pathways. Curr Opin Immunol. 2000; 12:276–281.
   PubMedGoogle Scholar
• Kurosaki T, Takata M, Yamanashi Y, Inazu T, Taniguchi T, Yamamoto T, Yamamura H. Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling. J Exp Med. 1994; 179:1725–1729.
   PubMed Web of Science ®Google Scholar
• Gold MR, Law DA, DeFranco AL. Stimulation of protein tyrosine phosphorylation by the B-lymphocyte antigen receptor. Nature. 1990; 345:810–813.
   PubMed Web of Science ®Google Scholar
• Hong JJ, Yankee TM, Harrison ML, Geahlen RL. Regulation of signaling in B cells through the phosphorylation of Syk on linker region tyrosines. A mechanism for negative signaling by the Lyn tyrosine kinase. J Biol Chem. 2002; 277:31703–31714.
   PubMed Web of Science ®Google Scholar
• Cambier JC. Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). J Immunol. 1995; 155:3281–3285.
   PubMed Web of Science ®Google Scholar
• Depoil D, Weber M, Treanor B, Fleire SJ, Carrasco YR, Harwood NE, Batista FD. Early events of B cell activation by antigen. Sci Signal. 2009; 2:pt1.
   PubMed Web of Science ®Google Scholar
• Jun JE, Goodnow CC. Scaffolding of antigen receptors for immunogenic versus tolerogenic signaling. Nat Immunol. 2003; 4:1057–1064.
   PubMed Web of Science ®Google Scholar
• Healy JI, Dolmetsch RE, Timmerman LA, Cyster JG, Thomas ML, Crabtree GR, Lewis RS, Goodnow CC. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity. 1997; 6:419–428.
   PubMed Web of Science ®Google Scholar
• Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene. 2004; 23:7990–8000.
   PubMed Web of Science ®Google Scholar
• van Oers NS. T cell receptor-mediated signs and signals governing T cell development. Semin Immunol. 1999; 11:227–237.
   PubMed Web of Science ®Google Scholar
• van Leeuwen JE, Samelson LE. T cell antigen-receptor signal transduction. Curr Opin Immunol. 1999; 11:242–248.
   PubMed Web of Science ®Google Scholar
• Chu P, Pardo J, Zhao H, Li CC, Pali E, Shen MM, Qu K, Yu SX, Huang BC, Yu P, Masuda ES, Molineaux SM, Kolbinger F, Aversa G, de Vries J, Payan DG, Liao XC. Systematic identification of regulatory proteins critical for T-cell activation. J Biol. 2003; 2:21.
   PubMedGoogle Scholar
• Krishnan S, Warke VG, Nambiar MP, Tsokos GC, Farber DL. The FcR gamma subunit and Syk kinase replace the CD3 zeta-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells. J Immunol. 2003; 170:4189–4195.
   PubMed Web of Science ®Google Scholar
• Lin J, Weiss A. T cell receptor signalling. J Cell Sci. 2001; 114:243–244.
   PubMed Web of Science ®Google Scholar
• Kadlecek TA, van Oers NS, Lefrancois L, Olson S, Finlay D, Chu DH, Connolly K, Killeen N, Weiss A. Differential requirements for ZAP-70 in TCR signaling and T cell development. J Immunol. 1998; 161:4688–4694.
   PubMed Web of Science ®Google Scholar
• Arpaia E, Shahar M, Dadi H, Cohen A, Roifman CM. Defective T cell receptor signaling and CD8+ thymic selection in humans lacking zap-70 kinase. Cell. 1994; 76:947–958.
   PubMed Web of Science ®Google Scholar
• Chan AC, Kadlecek TA, Elder ME, Filipovich AH, Kuo WL, Iwashima M, Parslow TG, Weiss A. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science. 1994; 264:1599–1601.
   PubMed Web of Science ®Google Scholar
• Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE. LAT: The ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell. 1998; 92:83–92.
   PubMed Web of Science ®Google Scholar
• Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, Furlong MT, Geahlen RL, Tybulewicz VL. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature. 1995; 378:298–302.
   PubMed Web of Science ®Google Scholar
• Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature. 1995; 378:303–306.
   PubMed Web of Science ®Google Scholar
• Cheng AM, Chan AC. Protein tyrosine kinases in thymocyte development. Curr Opin Immunol. 1997; 9:528–533.
   PubMed Web of Science ®Google Scholar
• Gilbert C, Barat C, Cantin R, Tremblay MJ. Involvement of Src and Syk tyrosine kinases in HIV-1 transfer from dendritic cells to CD4+T lymphocytes. J Immunol. 2007; 178:2862–2871.
   PubMed Web of Science ®Google Scholar
• Martelli MP, Lin H, Zhang W, Samelson LE, Bierer BE. Signaling via LAT (linker for T-cell activation) and Syk/ZAP70 is required for ERK activation and NFAT transcriptional activation following CD2 stimulation. Blood. 2000; 96:2181–2190.
   PubMed Web of Science ®Google Scholar
• Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34+bone marrow progenitor cells. J Immunol. 1991; 146:1410–1415.
   PubMed Web of Science ®Google Scholar
• Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008; 454:445–454.
   PubMed Web of Science ®Google Scholar
• Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev. 2009; 228:149–169.
   PubMed Web of Science ®Google Scholar
• Sada K, Zhang J, Siraganian RP. Point mutation of a tyrosine in the linker region of Syk results in a gain of function. J Immunol. 2000; 164:338–344.
   PubMed Web of Science ®Google Scholar
• Meng W, Sawasdikosol S, Burakoff SJ, Eck MJ. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature. 1999; 398:84–90.
   PubMed Web of Science ®Google Scholar
• Deckert M, Tartare-Deckert S, Couture C, Mustelin T, Altman A. Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product. Immunity. 1996; 5:591–604.
   PubMed Web of Science ®Google Scholar
• Zhang J, Siraganian RP. CD45 is essential for Fc epsilon RI signaling by ZAP70, but not Syk, in Syk-negative mast cells. J Immunol. 1999; 163:2508–2516.
   PubMed Web of Science ®Google Scholar
• Siraganian RP, Zhang J, Suzuki K, Sada K. Protein tyrosine kinase Syk in mast cell signaling. Mol Immunol. 2002; 38:1229–1233.
   PubMed Web of Science ®Google Scholar
• Benhamou M, Siraganian RP. Protein-tyrosine phosphorylation: An essential component of Fc epsilon RI signaling. Immunol Today. 1992; 13:195–197.
   PubMedGoogle Scholar
• Zou W, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ, Ginsberg MH, Ross FP, Teitelbaum SL. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol. 2007; 176:877–888.
   PubMed Web of Science ®Google Scholar
• Faccio R, Zou W, Colaianni G, Teitelbaum SL, Ross FP. High dose M-CSF partially rescues the Dap12 − / − osteoclast phenotype. J Cell Biochem. 2003; 90:871–883.
   PubMed Web of Science ®Google Scholar
• Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 2004; 428:758–763.
   PubMed Web of Science ®Google Scholar
• Desaulniers P, Fernandes M, Gilbert C, Bourgoin SG, Naccache PH. Crystal-induced neutrophil activation. VII. Involvement of Syk in the responses to monosodium urate crystals. J Leukoc Biol. 2001; 70:659–668.
   PubMed Web of Science ®Google Scholar
• Crowley MT, Costello PS, Fitzer-Attas CJ, Turner M, Meng F, Lowell C, Tybulewicz VL, DeFranco AL. A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages. J Exp Med. 1997; 186:1027–1039.
   PubMed Web of Science ®Google Scholar
• Barabe F, Gilbert C, Liao N, Bourgoin SG, Naccache PH. Crystal-induced neutrophil activation VI. Involvement of FcgammaRIIIB (CD16) and CD11b in response to inflammatory microcrystals. FASEB J. 1998; 12:209–220.
   PubMed Web of Science ®Google Scholar
• Ryckman C, Gilbert C, de Medicis R, Lussier A, Vandal K, Tessier PA. Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils. J Leukoc Biol. 2004; 76:433–440.
   PubMed Web of Science ®Google Scholar
• Kiefer F, Brumell J, Al-Alawi N, Latour S, Cheng A, Veillette A, Grinstein S, Pawson T. The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutrophils. Mol Cell Biol. 1998; 18:4209–4220.
   PubMed Web of Science ®Google Scholar
• Ng G, Sharma K, Ward SM, Desrosiers MD, Stephens LA, Schoel WM, Li T, Lowell CA, Ling CC, Amrein MW, Shi Y. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity. 2008; 29:807–818.
   PubMed Web of Science ®Google Scholar
• Bhagwat SS. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signal. 2009; 5:107–115.
   PubMed Web of Science ®Google Scholar
• Masuda ES, Schmitz J. Syk inhibitors as treatment for allergic rhinitis. Pulm Pharmacol Ther. 2008; 21:461–467.
   PubMed Web of Science ®Google Scholar
• Lai JY, Cox PJ, Patel R, Sadiq S, Aldous DJ, Thurairatnam S, Smith K, Wheeler D, Jagpal S, Parveen S, Fenton G, Harrison TK, McCarthy C, Bamborough P. Potent small molecule inhibitors of spleen tyrosine kinase (Syk). Bioorg Med Chem Lett. 2003; 13:3111–3114.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, Nakashima K, Ishimori M, Nagai H, Li YF, Yura T, Bacon KB. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther. 2003; 306:1174–1181.
   PubMed Web of Science ®Google Scholar
• Bhavaraju K, Kim S, Daniel JL, Kunapuli SP. Evaluation of [3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5-sulfonamide] (OXSI-2), as a Syk-selective inhibitor in platelets. Eur J Pharmacol. 2008; 580:285–290.
   PubMed Web of Science ®Google Scholar
• Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006; 319:998–1008.
   PubMed Web of Science ®Google Scholar
• Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP, Pine P, Firestein GS. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther. 2006; 317:571–578.
   PubMed Web of Science ®Google Scholar
• Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007; 124:244–257.
   PubMed Web of Science ®Google Scholar
• Rossi AB, Herlaar E, Braselmann S, Huynh S, Taylor V, Frances R, Issakani SD, Argade A, Singh R, Payan DG, Masuda ES. Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J Allergy Clin Immunol. 2006; 118:749–755.
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Hasegawa H, Seki H, Ziegelbauer K, Yasuda T. Development of a high-throughput fluoroimmunoassay for Syk kinase and Syk kinase inhibitors. Anal Biochem. 2003; 315:256–261.
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25:1271–1277.
   PubMed Web of Science ®Google Scholar
• Tsokos GC, Liossis SN. Immune cell signaling defects in lupus: Activation, anergy and death. Immunol Today. 1999; 20:119–124.
   PubMedGoogle Scholar
• Alvarado-de la Barrera C, Alcocer-Varela J, Richaud-Patin Y, Alarcon-Segovia D, Llorente L. Differential oncogene and TNF-alpha mRNA expression in bone marrow cells from systemic lupus erythematosus patients. Scand J Immunol. 1998; 48:551–556.
   PubMed Web of Science ®Google Scholar
• Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004; 50:3580–3590.
   PubMed Web of Science ®Google Scholar
• Inaoki M, Sato S, Weintraub BC, Goodnow CC, Tedder TF. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med. 1997; 186:1923–1931.
   PubMed Web of Science ®Google Scholar
• Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 2000; 165:6635–6643.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, DeFranco AL, Tedder TF. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity. 2000; 13:47–57.
   PubMed Web of Science ®Google Scholar
• Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC. Altered signal transduction in SLE T cells. Rheumatology (Oxford). 2007; 46:1525–1530.
   PubMed Web of Science ®Google Scholar
• Irving BA, Chan AC, Weiss A. Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J Exp Med. 1993; 177:1093–1103.
   PubMed Web of Science ®Google Scholar
• Rellahan BL, Jensen JP, Howcroft TK, Singer DS, Bonvini E, Weissman AM. Elf-1 regulates basal expression from the T cell antigen receptor zeta-chain gene promoter. J Immunol. 1998; 160:2794–2801.
   PubMed Web of Science ®Google Scholar
• Juang YT, Tenbrock K, Nambiar MP, Gourley MF, Tsokos GC. Defective production of functional 98-kDa form of Elf-1 is responsible for the decreased expression of TCR zeta-chain in patients with systemic lupus erythematosus. J Immunol. 2002; 169:6048–6055.
   PubMed Web of Science ®Google Scholar
• Enyedy EJ, Nambiar MP, Liossis SN, Dennis G, Kammer GM, Tsokos GC. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum. 2001; 44:1114–1121.
   PubMed Web of Science ®Google Scholar
• Tsokos GC, Nambiar MP, Tenbrock K, Juang YT. Rewiring the T-cell: Signaling defects and novel prospects for the treatment of SLE. Trends Immunol. 2003; 24:259–263.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, Delaney N, Tsokos GC. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol. 2004; 172:7821–7831.
   PubMed Web of Science ®Google Scholar
• Deng GM, Tsokos GC. Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J Immunol. 2008; 181:4019–4026.
   PubMed Web of Science ®Google Scholar
• Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum. 2008; 58:1433–1434.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Grossbard E.. Presentation: Treatment of rheumatoid arthritis (RA) with a Syk kinase inhibitor: A 12 week randomized placebo controlled study Annual Scientific Meeting by American College of Rheumatology. Abstract no 1189, 2008.
   Google Scholar